AbbVie Inc (ABBV) stock saw a decline, ending the day at $175.17 which represents a decrease of $-3.33 or -1.87% from the prior close of $178.5. The stock opened at $176.86 and touched a low of ...

Under the terms of the agreement, AbCellera will lead discovery activities and AbbVie has the right to develop and ...

Emraclidine was the centerpiece of AbbVie’s $8.7 billion acquisition of Cerevel in December 2023 but failed two mid-stage ...

Even before that deal, AbbVie had been showing an interest in the modality, with then-CEO Richard Gonzalez telling analysts ...

Czech National Bank increased its stake in shares of AbbVie Inc. (NYSE:ABBV – Free Report) by 6.5% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The ...

AbbVie (NYSE: ABBV) and REGENXBIO Inc. (Nasdaq: RGNX) today announced updates to the ABBV-RGX-314 clinical program.

This was the stock's second consecutive day of losses.

Simcere Zaiming, a subsidiary of Simcere Pharmaceutical Group Ltd (HKEX: 2096) and AbbVie Inc. (NYSE: ABBV) today announced ...

AbbVie Inc (ABBV) stock saw a decline, ending the day at $178.5 which represents a decrease of $-1.03 or -0.57% from the prior close of $179.53. The stock opened at $179.2 and touched a low of $176.18 ...

Investment analysts at Leerink Partnrs dropped their FY2024 EPS estimates for AbbVie in a research note issued to investors ...

The stock's fall snapped a three-day winning streak.